don't know capitalization yet, haven't cruised Edgar......
Tuesday August 15, 8:46 am Eastern Time
Press Release
SOURCE: Dyax Corp.
Dyax Corp. Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Aug. 15 /PRNewswire/ -- Dyax Corp. (Nasdaq: DYAX - news) today announced that it has priced
an initial public offering of 4,000,000 shares of common stock at $15.00 per share.
Dyax intends to use the net proceeds from the offering to fund research and development, possible acquisitions of technology
and complementary businesses, working capital needs, capital expenditures and for other general corporate purposes.
J.P. Morgan & Co. was the bookrunning lead manager for this offering. Lehman Brothers and Pacific Growth Equities, Inc.
acted as co-managers of this offering. Information about this offering is available in the prospectus filed with the Securities and
Exchange Commission.
Dyax is a biopharmaceutical company that has developed and patented a method, known as phage display, that Dyax is using
to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. Dyax is also using this
method to identify compounds that could be used in purifying and manufacturing biopharmaceuticals and other chemicals.
Copies of the final prospectus relating to the offering may be obtained from J.P. Morgan & Co., 60 Wall Street, New York,
NY 10260.
This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale in any
state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of
any such state.
Contact:
Henry Blair or
Stephen Galliker
Dyax Corp.
(617) 225-2500
Gretchen Schweitzer or
Wendy Soutsos
Feinstein Kean Healthcare
(617) 577-8110
SOURCE: Dyax Corp. |
